NeuroGAP-Psychosis
The first iteration of the Neuropsychiatric Genetics of African Populations-Psychosis study (NeuroGAP-Psychosis) was launched in 2016, with participant recruitment running from 2018 to 2023. NeuroGAP-Psychosis aimed to broaden our understanding of the genetic factors that contribute to psychosis. This genome-wide association study (GWAS) was carried out in partnership with the Harvard T.H. Chan School of Public Health and with five academic and research institutions in south and east Africa:
- Addis Ababa University, Ethiopia
- KEMRI-Wellcome Trust Research Programme, Kenya
- Moi University, Kenya
- University of Cape Town, South Africa
- Makerere University, Uganda
The NeuroGAP-Psychosis team — comprising researchers, clinicians, project managers, and others at Ó³»´«Ã½ and participating institutions — collected and sequenced saliva samples from 42,953 participants [half with a diagnosis of schizophrenia, bipolar disorder, schizoaffective disorder, or psychosis (cases) and those without any history of these conditions (controls)]. As of 2025, NeuroGAP-Psychosis 1.0 was the largest psychiatric genetics study conducted in Africa.
To learn more about NeuroGAP-Psychosis, read the published protocol and explore the multimedia content below.
A schizophrenia study in Africa is boosting equity in global genetic research.
